Breast cancer drug too expensive to be routinely available on nhs, watchdog rules _ health news _ lifestyle _ the independent
Read more Online calculator helps women predict their breast cancer risk
The manufacturer Roche offered a discount, but it was not enough to sway Nice to recommend the drug across England.
The drug will still be available in England through the Cancer Drugs Fund for some patients.
In Scotland, the organisation that decides which medicines should be routinely available on the NHS chose not to approve the drug last year.
Woman shares post-radiation images
to show reality of cancer
Mark & Spencer ads feature breast cancer survivors
Angelina Jolie’s double mastectomy improved breast cancer awareness
Breast Cancer Awareness Month 2015: 10 best beauty products
Nice said Roche had agreed a “significant” discount with NHS England to stop the drug being removed from the CDF, but a smaller discount had been offered to Nice for the drug’s more widespread use.
This means women will need to ask their oncologist to apply to the CDF for funding for Kadcyla.
It is licensed for HER2-positive breast cancer and has been shown to extend life by almost six months on average in women who have tried other treatments, although some patients live much longer.
The Government should introduce a sugar tax to prevent an “obesity crisis” from crippling the NHS, a senior Conservative MP and former health minister has said. Dr Dan Poulter believes that the case for increased taxes on unhealthy sugary products was “increasingly compelling”
Cancer breakthrough offers new hope for survivors rendered infertile by chemotherapy
A potentially “phenomenal” scientific breakthrough has offered fresh hope to cancer patients rendered infertile by chemotherapy. For the first time, researchers managed to restore ovaries in mice affected by chemotherapy so that they were able to have offspring. The scientists now plan to begin clinical trials to see if the technique, which involves the use of stem cells, will also work in humans by using umbilical cord material and possibly stem cells taken from human embryos, if regulators agree
Take this NHS test to find out if you have a cancerous mole
An interactive test could help flag up whether you should seek advice from a health professional for one of the most common types of cancer. The test is available on the NHS Choices website and reveals whether you are at risk from the disease and recommends if you should seek help. The mole self-assessment factors in elements such as complexion, the number of times you have been severely sunburnt and whether skin cancer runs in your family. It also quizzes you on the number of moles you have and whether there have been any changes in appearance regarding size, shape and colour
Health apps approved by NHS ‘may put users at risk of identity theft’
Experts have warned that some apps do not adequately protect personal information
The vegetables that ‘could be making people overweight’
Potatoes have emerged as a potential vegetable that could make people gain weight, due to their high starch and low water content
A watchdog has said that care visits must last longer
The National Institute for Health and Care Excellence (Nice) said home help visits of less than 30 minutes were not acceptable unless part of a wider package of support
Pendle in Lancashire tops list of five most anxious places to live in the UK
Pendle in Lancashire has been named the most anxious place to live in the UK, while people living in Fermanagh and Omagh in Northern Ireland have been found to be the happiest
Ketamine could be used as anti-depressant
Researchers at the University of Auckland said monitoring the effects of the drug on the brain has revealed neural pathways that could aid the development of fast-acting medications.
Ketamine is a synthetic compound used as an off anaesthetic and analgesic drug, but is commonly used illegally as a hallucinogenic party drug.
Dr Suresh Muthukumaraswamy, a senior researcher at the university and a member of the institution’s Centre for Brain Research, used the latest technology in brain imaging to investigate what mechanisms ketamine uses to be active in the human brain
A prosthetic hand that lets people actually feel through
The technology lets paralysed people feel actual sensations when touching objects — including light taps on the mechanical finger — and could be a huge breakthrough for prosthetics, according to its makers. The tool was used to let a 28-year-old man who has been paralysed for more than a decade. While prosthetics have previously been able to be controlled directly from the brain, it is the first time that signals have been successfully sent the other way
The biggest cause of early death in the world is what you eat
Unhealthy eating has been named as the most common cause of premature death around the globe, new data has revealed. A poor diet – which involves eating too few vegetables, fruits, nuts and grains and too much red meat, salt and sugar – was shown to be a bigger killer than smoking and alcohol
Scientists develop blood test that estimates how quickly people age
Scientists believe it could be used to predict a person’s risk of developing Alzheimer’s disease as well as the “youthfulness” of donated organs for transplant operations. The test measures the vitality of certain genes which the researchers believe is an accurate indication of a person’s “biological age”, which may be younger or older than their actual chronological age
Aspirin could help boost therapies that fight cancer
The latest therapies that fight cancer could work better when combined with aspirin, research has suggested. Scientists from the Francis Crick Institute in London say the anti-inflammatory pain killer suppresses a cancer molecule that allows tumours to evade the body’s immune defences.
Laboratory tests have shown that skin, breast and bowel cancer cells often generate large amounts of this molecule, called prostaglandin E2 (PGE2).
But Aspirin is one of a family of drugs that sends messages to the brain to block production of PGE2 and this means cancer cells can be attacked by the body’s natural defences
Sir Andrew Dillon, chief executive of Nice, said: “We recognise that Kadcyla has a place in treating some patients with advanced breast cancer. However, the price that the manufacturer is asking the NHS to pay in the long term is too high.
“Despite a growing public campaign for a fair deal on the cost of important new cancer medicines, it is disappointing that there appears to have been no meaningful attempt by Roche to reconsider its price to secure Kadcyla’s long-term future in the NHS, outside of the Cancer Drugs Fund.”
Dr Caitlin Barrand, assistant director of policy and campaigns at Breast Cancer Now, said it was “hugely disappointing news”.